Management Change19 Jun 2026, 05:22 pm
Albert David Appoints Amit Mahla as Whole-time Director & CEO
AI Summary
Albert David Ltd has announced the appointment of Mr. Amit Mahla as an Additional Director and Whole-time Director & CEO, effective June 19, 2026. This appointment is for a term of 5 years, concluding on June 18, 2031, and is subject to shareholder approval at the upcoming 87th Annual General Meeting (AGM). Mr. Mahla, who also serves as the company's CEO since May 12, 2026, brings over 28 years of experience in the pharmaceutical industry, with a strong background in business transformation and strategic leadership. His remuneration for the period June 19, 2026, to March 31, 2027, has also been fixed, pending shareholder approval.
Key Highlights
- Amit Mahla appointed Additional Director and Whole-time Director & CEO.
- Appointment is for a 5-year term, effective June 19, 2026.
- Subject to shareholder approval at the 87th AGM.
- Mahla brings over 28 years of pharmaceutical industry experience.
- Remuneration fixed, pending shareholder approval.
Price Impact
More from ALBERTDA